IPRs at the PTAB

Engelberg Center Executive Director Anne Hassett moderated a panel discussion among industry representatives, including the pharmaceutical and high tech industries, on whether innovation is better supported by having the Patent Trial and Appeal Board (PTAB) apply in inter partes review (IPR) proceedings the same legal standards that US District Courts apply in patent litigation or the standards which the USPTO applies in patent prosecution. Panelists included: Matthew Levy, Computer and Communications Industry Association; Hans Sauer, Biotechnology Industry Organization; Jaime A. Siegel, ACACIA Research Group LLC; Marian Underweiser, IP Policy & Strategy, IBM; Jane Wasman, Acorda Therapeutics, Inc.